Educational information only. EyeCyte does not provide medical advice, diagnosis or treatment. Research discussed here may be experimental, investigational or unapproved. Research-Use-Only (RUO) materials are not for human use. Full disclaimer · RUO policy

Limbal Stem Cell Deficiency & Corneal Damage and Regenerative Medicine Research

Last medically reviewed: October 7, 2026

What is limbal stem cell deficiency & corneal damage?

Limbal stem cell deficiency (LSCD) occurs when the stem cells at the edge of the cornea (the limbus) are damaged or lost, so the corneal surface can no longer renew itself normally. Chemical and thermal burns are common causes.

What causes limbal stem cell deficiency & corneal damage?

Chemical or thermal injury, certain inflammatory diseases, contact-lens-related injury, surgery and some genetic conditions.

What structures or cells are affected?

The limbal stem cells and the corneal epithelium.

How is limbal stem cell deficiency & corneal damage currently treated or managed?

● Established / Approved
  • Management by a cornea specialist.
  • Depending on severity, surgical approaches that transplant limbal tissue from the healthy eye or a donor.

Are these approaches FDA approved for limbal stem cell deficiency & corneal damage?

● Established / Approved In the European Union, a cultivated autologous limbal stem cell product (Holoclar) received conditional marketing authorisation in 2015 for LSCD after eye burns. This is an EU authorisation, not an FDA approval.[1]

We are not aware of an FDA-approved cultivated limbal stem cell product as of our last review; confirm current status with a cornea specialist.[3]

Why are researchers studying regenerative approaches?

Limbal stem cells are the eye's own corneal-surface stem cells — one of the few areas where stem-cell-based approaches have reached established clinical use in some jurisdictions.

Research is not treatment. The studies summarized below are investigational. They are presented for education only, do not show that any approach is safe or effective in patients, and are not a recommendation. Unless stated as FDA-approved, none of these approaches is approved for this condition. RUO materials are not for human use.

Stem Cell Research and Limbal Stem Cell Deficiency & Corneal Damage

  • ● Human Clinical EvidenceLimbal Stem Cells

    Long-term clinical follow-up of cultivated limbal stem cell transplantation for burn-related LSCD has been published.[2]

MSC Research and Limbal Stem Cell Deficiency & Corneal Damage

Extracellular Vesicle / Exosome Research and Limbal Stem Cell Deficiency & Corneal Damage

We have not identified research in this category for limbal stem cell deficiency & corneal damage that meets our standards for inclusion.

Other Cell-Based Research

We have not identified research in this category for limbal stem cell deficiency & corneal damage that meets our standards for inclusion.

What Has Been Demonstrated in Laboratory Research?

We have not identified research in this category for limbal stem cell deficiency & corneal damage that meets our standards for inclusion.

What Has Been Demonstrated in Animal Research?

What Human Research Exists?

  • ● Human Clinical EvidenceLimbal Stem Cells

    Long-term clinical follow-up of cultivated limbal stem cell transplantation for burn-related LSCD has been published.[2]

Are Clinical Trials Underway?

Trial status changes often. Search the official U.S. registry directly: Limbal Stem Cell Deficiency + limbal. A registered trial is not an endorsement, and registration does not mean a treatment works.

What Has NOT Yet Been Proven

● Insufficient Evidence
  • That MSC or exosome products are effective for LSCD.

Potential Biological Mechanisms Researchers Are Investigating

● Mechanistic / Theoretical

Risks and Scientific Unknowns

  • Unapproved cell and biologic procedures offered outside clinical trials have been associated with serious harm, including permanent vision loss.
  • Products sold as "stem cells" or "exosomes" vary widely in what they actually contain; composition, purity and potency are often not independently verified.
  • Results in cells and animals frequently do not carry over to people; many approaches that look promising in the laboratory never reach approval.

Questions to Ask a Qualified Eye Doctor

  • What type and stage of this condition do I have, and how is it likely to progress?
  • Which treatments are established for my situation, and what are their benefits and risks?
  • Are there clinical trials I might qualify for, and how would I verify a trial is legitimate?
  • If I have seen a clinic offering stem cell or exosome procedures for my eyes, what questions should I ask?

Find an Eye-Care Professional

EyeCyte does not provide medical care. Browse the provider directory by specialty and location, or send us a request. Listing in a directory is not an endorsement of any experimental intervention.

Open the provider directory →

Protected by reCAPTCHA. Google’s Privacy Policy and Terms apply.

Information for Physicians and Researchers

Professional education, research summaries and research-use-only materials are on our professional pages — kept separate from patient information.

Explore Limbal Stem Cell Deficiency & Corneal Damage

Related research questions

Related conditions: Dry Eye Disease

Frequently Asked Questions

Is limbal stem cell transplantation the same as a stem cell clinic injection?

No. Limbal stem cell transplantation is a specialized surgical approach for a specific condition, performed by cornea surgeons.

Is any stem cell or exosome product FDA approved for limbal stem cell deficiency & corneal damage?

We are not aware of an FDA-approved cultivated limbal stem cell product as of our last review; confirm current status with a cornea specialist.

References

  1. Holoclar — European public assessment report. European Medicines Agency, 2015. [Regulator · citation details pending reviewer confirmation]
  2. Rama P, et al. Limbal Stem-Cell Therapy and Long-Term Corneal Regeneration. New England Journal of Medicine, 2010. [Peer-reviewed study · citation details pending reviewer confirmation]
  3. Approved Cellular and Gene Therapy Products. U.S. Food and Drug Administration. [Regulator · citation details pending reviewer confirmation]
  4. FDA Warns About Stem Cell Therapies (consumer update). U.S. Food and Drug Administration. [Regulator · citation details pending reviewer confirmation]
Live searches (always current)